The CANTOS trial: Implications for the management of patients with residual risk - PACE-CME

The CANTOS trial Implications for the management of patients with residual risk

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Perspectives on CKM syndrome
Perspectives on CKM syndrome
AHA 2024
Perspectives on CKM syndrome
- Javed Butler, MD
Predicting 30-year CV outcomes in women
Predicting 30-year CV outcomes in women
ESC Congress 2024
Predicting 30-year CV outcomes in women
- Paul Ridker, MD
Exciting times to address residual inflammatory risk
Exciting times to address residual inflammatory risk
EAS 2024
Exciting times to address residual inflammatory risk
- Peter Libby, MD
Pro/con debate: Are we ready to treat inflammation for ASCVD prevention?
Pro/con debate: Are we ready to treat inflammation for ASCVD prevention?
EAS 2024
Pro/con debate: Are we ready to treat inflammation for ASCVD prevention?
- Ulrich Laufs, MD, PhD
- Paul Ridker, MD